COVAX aims to accelerate the development and manufacture of COVID-19 vaccines and guarantee access to all countries.
Photo illustration by STR/NurPhoto via Getty Images
Researchers say around 70% of the US needs to get the coronavirus vaccine to stop the pandemic. But questions around the vaccines and regional differences add some uncertainty to that estimate.
Getting vaccines to rural and hard-to-reach areas is critical for public health and ethical reasons.
Hector Roqueta Rivero/Moment via Getty Images
So far, the only COVID-19 vaccines authorized for use need to be kept frozen. But there are many places in the world that can’t support a cold supply chain.
The French government will not accept any passengers arriving from the U.K. amid fears over the new mutant coronavirus strain.
Steve Parsons/PA Images via Getty Images
A new strain of the SARS-CoV-2 virus that causes COVID-19 appears to be spreading fast in the UK. This probably isn’t a big problem, but the data isn’t in yet.
Efficient shipping and storage could prevent a lot of wasted vaccines.
AP Photo/Morry Gash, Pool
COVID-19 vaccines have very specific storage requirements that make shipping a difficult task. Two ideas – fulfillment centers and cross-docking – could help overcome some distribution challenges.
The pharmaceutical industry opposes the suspension of intellectual property rights on COVID-19 vaccines and treatments, and no pharma companies have yet contributed to the COVID-19 Technology Access Pool.
(Shutterstock)
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
Although monetary incentives work, there are potential drawbacks.
Joel Saget/AFP via Getty Images
Wesley Kufel, Binghamton University, State University of New York
COVID-19 vaccine testing on children is just getting started, and only in adolescents.
Tony Potts, a 69-year-old retiree, removes his face mask for a temperature check just before receiving his first injection in a phase 3 COVID-19 vaccine clinical trial sponsored by Moderna. Potts is one of 30,000 participants in the Moderna trial.
Paul Hennessy/NurPhoto via Getty ImageS
The vaccines that will first be used to prevent the spread of COVID-19 will have gone through a special approval process with the FDA. but just what is this expedited process?
A little bit of post-injection soreness is completely normal.
Jose Luis Pelaez Inc/DigitalVision via Getty Images
The side effects of new SARS-CoV-2 vaccines are a result of immune system activation. While uncomfortable, they are both normal and expected. They are a sign that the vaccine is working.
Elvis Presley received a polio vaccination on the Ed Sullivan Show in 1956.
neftali/Shutterstock.com
Pfizer and BioNTech have announced 95% efficacy for their mRNA vaccine, having met the final target they need to before seeking regulatory approval.
A volunteer gets an injection of Moderna’s possible COVID-19 vaccine on July 27, 2020. Moderna announced Nov. 16 that its vaccine is proving highly effective in a major trial.
(AP Photo/Hans Pennink)
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
Moderna’s new mRNA vaccine is almost 94.5% effective in large-scale trials.
JUSTIN TALLIS/AFP via Getty Images
There are two new COVID-19 vaccines that appear to be more than 90% effective. But what are these vaccines, and how are they different from those used previously?
Moderna’s shot is far easier to store and distribute than Pfizer’s. But there are concerns neither vaccine performs particularly well for older people.
Interim analysis of trial data isn’t unusual – but leaves us with many things we still need to find out.
Pfizer stock surged higher on Nov. 9 after the company announced its vaccine is “90% effective” against COVID-19 infections.
KENA BETANCUR/AFP via Getty Images
With COVID-19 cases soaring across the US and worldwide, the need for a vaccine could not be greater. Here’s where we stand on vaccine development, including positive results from Pfizer’s trial.
Early analysis suggests this vaccine has an efficacy of over 90%. So if you took ten people who were going to get sick from COVID-19 and vaccinated them, only one would get sick.
Dean Faculty of Health Sciences and Professor of Vaccinology at University of the Witwatersrand; and Director of the SAMRC Vaccines and Infectious Diseases Analytics Research Unit, University of the Witwatersrand
Paediatrician at the Royal Childrens Hospital and Associate Professor and Clinician Scientist, University of Melbourne and MCRI, Murdoch Children's Research Institute